StockNews.AI
LSB
StockNews.AI
19 days

LakeShore Biopharma Announces Fiscal Year 2025 Financial Results

1. LakeShore Biopharma reports 7.2% revenue growth and 11.3% gross profit increase. 2. Net loss decreased significantly, signaling improving financial health for LSB.

3m saved
Insight
Article

FAQ

Why Bullish?

The company's positive revenue and profit growth indicate strong operational performance. Historically, consistent revenue growth has been linked to stock price increases in biotech firms.

How important is it?

The financial performance displayed is crucial for LSB’s credibility and market perception, significantly impacting investor confidence.

Why Short Term?

Financial results can influence stock price immediately as investor sentiment shifts. Quick investor reactions to earnings reports are common in the biopharma sector.

Related Companies

BMYMRNAPFEJNJ
Total revenue reached RMB615.0 million, representing 7.2% year-over-year growth Gross profit rose to RMB507.2 million, up 11.3% year-over-year Gross margin improved to 82.5% from 79.5% in Fiscal Year 2024 Total operating expenses decreased 34.2% year-over-year to RMB593.5 million EBITDA[1] and Adjusted EBITDA[2] were RMB(48.5 million) and RMB0.6 million, respectively, compared to RMB(368.7 million) and RMB(236.4 million) in Fiscal Year 2024 Net loss narrowed to RMB100.0 million, with an adjusted net loss[3] of RMB40.0 million, compared to RMB433.5 million and RMB266.3 million, respectively, in Fiscal Year 2024 BEIJING , July 31, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its financial results for the Fiscal Year ended March 31, 2025 ("FY2025"). "We are pleased to announce LakeShore Biopharma's FY2025 financial results with a 7.2% year-over-year growth in revenues and an 11.3% year-over-year growth in gross profits.

Related News